Synthesis, SAR and evaluation of [1,4′]-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 11, 2010, Pages 3219-3222

  Rotstein, David M ^a   Gabriel, Stephen D ^a   Manser, Nicole ^a   Filonova, Lubov ^a   Padilla, Fernando ^a   Sankuratri, Surya ^a   Ji, Changhua ^a   deRosier, Andre ^a   Dioszegi, Marianna ^a   Heilek, Gabrielle ^a   Jekle, Andreas ^a   Weller, Paul ^a   Berry, Pamela ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

Anti HIV 1; Antiviral; CCR5 Antagonist; Chemokine

Indexed keywords

(1,4')BIPIPERIDINYL 4 YL IMIDAZOLIDIN 2 ONE DERIVATIVE; ANTIVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; IMIDAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL LINE; DRUG EVALUATION, PRECLINICAL; HUMANS; IMIDAZOLIDINES; RATS; RECEPTORS, CCR5; STRUCTURE-ACTIVITY RELATIONSHIP;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77953286467     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.04.077     Document Type: Article

References (16)

1. Kuritzkes D., Kar S., and Kirkpatrick P. Nat. Rev. Drug Disc. 7 (2008) 15
2. Turner J.E., Steinmetz O.M., Stahl R.A., and Panzer U. Mini-Rev. Med. Chem. 7 (2007) 1089
3. Rotstein D.M., Gabriel S.D., Makra F., Filonova L., Gleason S., Brotherton-Pleiss C., Setti L.Q., Trejo- Martin A., Lee E.K., Sankuratri S., Ji C., deRosier A., Dioszegi M., Heilek G., Jekle A., Berry P., Weller P., and Maul C.-I. Bioorg. Med. Chem. Lett. 19 (2009) 5401
4. Zhou, Y.; Bourque, E.; Zhu, Y.; Langille, J.; Metz, M.; Yang, W.; Mceachern, E. J.; Harwig, C.; Baird, I. R.; Li, T-S.; Skerlj, R. T. WO2006138350.
5. Zhou, Y.; Bourque, E.; Zhu, Y.; McEachern, E. J.; Harwig, C.; Skerlj, R. T.; Bridger, G. J.; Li, T.-S.; Metz, M. WO2007022371.
6. Subsequent to our investigative efforts, related templates have been reported: Bourque, E.; Metz, M.; Baird, I. R.; Yang, W.; Bridger, G.; Skerlj, R. T. WO2008070758.
7. For binding and antiviral assay protocols see: Melville, C. R.; Rotstein, D. M. WO2008119663.
8. The thresholds above which intrinsic microsomal clearance values were considered to be high were ≥35 μl/min/mL for HLM, ≥90 μl/min/mL for RLM and ≥43 μl/min/mL for kfLM (cynomologous monkey). These scaled to in vivo clearance values ≥70% of liver blood flow using the well-stirred model. Intrinsic microsomal clearance values corresponding to ≤30% of liver blood flow (≤6.5 μl/min/mL for HLM, ≤15 μl/min/mL for RLM and (≤14 μl/min/mL for kFLM) were considered to be low.
9. Obach R.S. Curr. Opin. Drug Disc. Dev. 4 (2001) 36
10. Van Breemen R.B., and Li Y. Expert Opin. Drug Metab. Toxicol. 1 (2005) 175
11. -6 cm/s.
12. Screening in Caco-2 cells with Pgp inhibitors such as elacridar (gf12098) to suppress active transport and assess intrinsic permeability is well established (cf. Hochman, J. H.; Yamazaki, M.; Ohe, T.; Lin, J. H. Curr. Drug Metab. 2002, 3, 257.) Screening of our analogs in this way resulted in restoration of good intrinsic permeability and elimination of efflux.
13. Ernst J., Dahl R., Lum L., Sebo L., Urban J., Miller S.G., and Lundstrom J. Bioorg. Med. Chem. Lett. 18 (2008) 1498
14. Ly J.Q., Shy G., and Misner D.L. Clin. Lab. Med. 27 (2007) 201
15. For more detailed experimental information, see: Gabriel, S. D.; Lemoine, R.; Rotstein, D. M.; Wanner, J. WO2009013171.
16. Thoma G., Nuninger F., Schaefer M., Akyel K.G., Albert R., Beerli C., Bruns C., Francotte E., Luyten M., MacKenzie D., Oberer L., Streiff M.B., Wagner T., Walter H., Weckbecker G., and Zerwes H.-G. J. Med. Chem. 47 (2004) 1939